Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PAVmed Inc. - Series Z Warrant (NQ:PAVMZ)

0.0055 +0.0001 (+1.85%)
Streaming Delayed Price Updated: 10:19 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105
Open 0.0055
Bid (Size) 0.0049 (5)
Ask (Size) 0.0052 (1)
Prev. Close 0.0054
Today's Range 0.0055 - 0.0055
52wk Range 0.0028 - 0.0720
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PAVmed and Lucid Diagnostics Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire

Performance

YTD
-45.0%
-45.0%
1 Month
+10.0%
+10.0%
3 Month
-45.0%
-45.0%
6 Month
-54.5%
-54.5%
1 Year
-81.7%
-81.7%

More News

Read More
PAVmed Partners with Novosound on Ultrasound Imaging Technology
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed to Participate in BTIG Digital Health Forum
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference
From PAVmed Inc.
Via Business Wire
PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
From Lucid Diagnostics Inc.
Via Business Wire
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy’s 2022 Most Influential Black Executives in Corporate America
From PAVmed Inc.
Via Business Wire
PAVmed to Hold a Business Update Conference Call on May 12, 2022
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From PAVmed Inc.
Via Business Wire
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
From PAVmed Inc.
Via Business Wire
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
From PAVmed Inc.
Via Business Wire
PAVmed Appoints Shaun O’Neil as Chief Operating Officer
From PAVmed Inc.
Via Business Wire
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
From PAVmed Inc.
Via Business Wire

Frequently Asked Questions

Is PAVmed Inc. - Series Z Warrant publicly traded?
Yes, PAVmed Inc. - Series Z Warrant is publicly traded.
What exchange does PAVmed Inc. - Series Z Warrant trade on?
PAVmed Inc. - Series Z Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for PAVmed Inc. - Series Z Warrant?
The ticker symbol for PAVmed Inc. - Series Z Warrant is PAVMZ on the Nasdaq Stock Market
What is the current price of PAVmed Inc. - Series Z Warrant?
The current price of PAVmed Inc. - Series Z Warrant is 0.0055
When was PAVmed Inc. - Series Z Warrant last traded?
The last trade of PAVmed Inc. - Series Z Warrant was at 04/04/25 10:19 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.